DAM
CERE

DLD Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

DLD Asset Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,500
Closed -$697K – 103
2024
Q1 		$697K Buy
+16,500
New +$693K 0.1% 55

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DLD Asset Management's CERE Position: Q2 2024 in Review

DLD Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 16,500 shares — an estimated $697K sold.

DLD Asset Management first reported a position in CERE in Q1 2024 and held it in 1 quarter. The position peaked at $697K in Q1 2024. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • DLD Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • DLD Asset Management sold 16,500 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $697K.
  • DLD Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • DLD Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $697K in Q1 2024.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on DLD Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.